Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The purpose of the study COVID-EP is to classify all the complications occurring after the diagnosis of pulmonary embolism in patients tested initially COVID-19 positive and negative by RT-PCR (on nasopharyngeal sample) during the peak of the pandemic in France (April 2020). The patients will be followed for 1 year in order to provide clinical and paraclinical data not yet published in the literature. In order to secondarily confirm the COVID-19 status of initially negative COVID-19 patients (by RT-PCR), a serology test will be performed. The collected complications will then be compared between each of the 3 following groups: [PCR-COVID 19-Neg & Sero-COVID 19-Neg] versus [PCR-COVID 19-Neg & Sero-COVID 19-Pos] versus [PCR-COVID 19-Pos].
Description: PE complications : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: % of patients for each group presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 6 months after PE diagnosis. Time: 6 months after PE diagnosisDescription: PE complications : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: % of patients for each group and subgroup presenting the occurrence of PE complications defined by the occurrence of at least ONE of the following events up to 12 months after PE diagnosis. Time: 12 months after PE diagnosisDescription: PE complications : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: % of patients in each group presenting the occurrence of each of the following events at each follow-up (3 months, 6 months and 12 months after PE diagnosis). Time: 3, 6 and 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC PE complication : Chronic interstitial pathology, or Recurrence of PE, or Pulmonary hypertension, or Death.
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: % of occurrence of PE complications for each categories of treatments Time: 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC Bleeding complications: classification 1-2-3-5 according to BARC
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with occurrence of bleeding complications for each categories of treatments Time: 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: % of patients with no occurrence of complications for each categories of treatments Time: 12 months after PE diagnosisDescription: Category of treatments: Heparin + AVK Heparin + DOAC
Measure: Effectiveness of the different category of treatments used in all patients and in the groups: duration of Heparin treatment (number of day) Time: 12 months after PE diagnosis